Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

CLLS

Cellectis S.A.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

  • CLLSCellectis S.A.
    0Calm

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

    Signing up patientsPhase 1/252 patientsMain results: Jun 30, 2026
  • CLLSCellectis S.A.
    0Calm

    Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

    Signing up patientsPhase 1/280 patientsMain results: Aug 2027

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 0 purchases

No insider sales or purchases in the last 6 months.

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

  • None in the last 12 months.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.